Bristol-Myers Squibb stock (US0897961004): Swiss Life Asset Management boosts stake

Swiss Life Asset Management Ltd acquired additional shares in Bristol-Myers Squibb on May 11, 2026, signaling institutional interest amid Q1 revenue growth of 2.6% year-over-year.

Bristol-Myers Squibb Company shares drew attention after Swiss Life Asset Management Ltd reported acquiring additional BMY stock in a recent filing. This move by the Swiss investor highlights ongoing institutional confidence in the pharmaceutical giant. The company also posted quarterly revenue up 2.6% year-over-year, with a return on equity of 64.87% and net margin of 15.01%, according to MarketBeat as of 05/11/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb Company
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, immunology, cardiovascular drugs
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD

Bristol-Myers Squibb Company: core business model

Bristol-Myers Squibb Company develops and markets innovative medicines targeting serious diseases. The company focuses on oncology, hematology, immunology, cardiovascular, and fibrosis areas. Its portfolio includes blockbuster drugs like Opdivo for cancer immunotherapy and Eliquis for blood clot prevention, marketed in collaboration with Pfizer. These products drive the majority of revenue, with a global footprint emphasizing the US market where it generates over half of sales.

The business model relies on a robust R&D pipeline, investing billions annually in clinical trials and new therapies. Bristol-Myers Squibb employs a strategy of acquisitions and partnerships to bolster its lineup, such as the blockbuster Celgene deal in 2019. For US investors, its NYSE listing and exposure to the world's largest pharma market make it a key player in healthcare portfolios.

Main revenue and product drivers for Bristol-Myers Squibb Company

Key products include Opdivo (nivolumab), which generated billions in 2025 sales from cancer treatments, and Eliquis (apixaban), a leading anticoagulant with steady demand. Revlimid, from the Celgene acquisition, remains a hematology staple despite patent cliffs. Recent quarterly revenue rose 2.6% year-over-year, reflecting resilience amid patent expirations, per MarketBeat as of 05/11/2026.

Immunology drugs like Orencia and emerging therapies in fibrosis contribute to diversification. The stock traded around $56 USD on NYSE recently, with a dividend yield of 4.53% and quarterly payout of $0.63, ex-date January 2, 2026, according to Google Finance as of 05/11/2026. EPS stood at $3.56, underscoring profitability for income-focused US investors.

Industry trends and competitive position

The pharma sector faces patent cliffs but benefits from oncology and immunology growth. Bristol-Myers Squibb competes with Pfizer, Merck, and Roche, holding strong in checkpoint inhibitors. Its US market dominance, with major revenue from American payers, positions it well amid rising healthcare spending projected by sector analysts.

Why Bristol-Myers Squibb Company matters for US investors

Listed on NYSE, Bristol-Myers Squibb offers US investors direct access to a dividend aristocrat with 4.53% yield and exposure to the $500B+ US pharma market. Institutional buys like Swiss Life's stake increase signal stability, relevant for retirement portfolios tracking S&P 500 healthcare.

Conclusion

Swiss Life Asset Management's share acquisition underscores institutional interest in Bristol-Myers Squibb amid solid Q1 metrics like 2.6% revenue growth and high ROE. The company's focus on high-demand therapies positions it in a competitive pharma landscape. US investors note its NYSE presence and dividend appeal, though patent dynamics warrant monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.